Research programme: monoclonal antibodies - argenx/Shire

Drug Profile

Research programme: monoclonal antibodies - argenx/Shire

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator arGEN-X
  • Developer argenx
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 27 Feb 2017 argenx extends collaboration with Shire Pharmaceuticals for development of therapeutic antibodies
  • 18 Feb 2015 arGEN-X in-licenses GS Xceed™ System technology from Lonza
  • 04 Jun 2014 arGEN-X enters into a long-term strategic collaboration with Shire Pharmaceuticals for the discovery and development of differentiated therapeutic antibodies against multiple targets of interest to Shire
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top